Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Issued (2016 - 2025)

Historic Shares Issued for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $11.8 million.

  • Viridian Therapeutics, Inc.\DE's Shares Issued fell 9690.52% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.8 million, marking a year-over-year decrease of 8300.42%. This contributed to the annual value of $453.7 million for FY2024, which is 26272.78% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Shares Issued of $11.8 million as of Q3 2025, which was down 9690.52% from $763000.0 recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Shares Issued ranged from a high of $382.7 million in Q3 2024 and a low of $4000.0 during Q2 2022
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Shares Issued value was $6.9 million (recorded in 2023), while the average stood at $50.5 million.
  • In the last 5 years, Viridian Therapeutics, Inc.\DE's Shares Issued crashed by 9994.73% in 2022 and then soared by 5372573.84% in 2024.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Shares Issued (Quarter) stood at $32.4 million in 2021, then dropped by 22.57% to $25.1 million in 2022, then skyrocketed by 359.57% to $115.3 million in 2023, then plummeted by 39.36% to $69.9 million in 2024, then crashed by 83.06% to $11.8 million in 2025.
  • Its Shares Issued was $11.8 million in Q3 2025, compared to $763000.0 in Q2 2025 and $2.3 million in Q1 2025.